ACO BOARD OF DIRECTORS MEETING
February 9, 2022 5:30PM

The Regular meeting of the ACO Board of Directors was held electronically via TEAMS video conference.

I. NOTICE

Notice of this meeting is attached to the official Minutes as EXHIBIT I. The official Agenda for this meeting, as presented for the consideration of the Board, is attached to the Minutes as EXHIBIT II and EXHIBIT III.

II. CALL TO ORDER

There being a quorum present, the meeting was called to order by Chair Foster, M.D. at 5:35 PM.

III. ROLL CALL:

BOARD MEMBERS

Present: Keith Foster, M.D. President
Jon Albee
Aldo Calvo, DO
Jerry Capote, MD
Husman Khan, MD
Joshua Lenchus, DO
Avinash Persad, MD

Additionally Present: Alisa Bert, ACO Officer, VP Financial Services; Alex Fernandez, Chief Financial Officer; Gavin Malcolm, Director, Population Health; Alessi Rodriguez, Coordinator Clinical Integration and Operations; Gerald DelAmo, Deputy General Counsel; Nicholas Ortiz, Sr. Associate, General Counsel; Ken Hetlage, Interim Chief Operating Officer

IV. PUBLIC COMMENTS: None

V. APPROVAL OF ACO MINUTES – (EXHIBIT 11)

Chair Foster entertained a motion to approve the January 12, 2022 ACO Board Meeting Minutes.

MOTION: It was moved by Jon Albee, seconded by Dr. Calvo to:

Approve the minutes dated January 12, 2022 with changes as recommended by Mr. Albee noted
Motion carried unanimously.
VI. **SUBCOMMITTEE UPDATES:** Mr. Malcolm reported:

A. **Clinical Outcomes and Utilization:** For Cigna, all but one quality metric is in the green. Pediatric well child visits dropped but it was due to one patient. Mr. Malcolm noted the Generic Dispensing Rate is 87.7% as before but that the Generic Efficiency Rate remains high at 99.7%, which means almost all of the medications that have a generic option are being utilized.

Mr. Malcolm noted that for Cigna utilization, ER visits per 1,000 is below the market and has a 6.9% improvement against the market. Mr. Malcolm noted the Potentially Avoidable ER visits per 1,000 is slightly higher than the market but the ratio has improved by 17.7% from the last quarter against the market. The ACSC ER visits is well below the market, showing a 33.1% improvement from last quarter. The High Utilization ER visits is dramatically below the market with a 66.7% improvement from last quarter. Mr. Malcolm noted some of the results are due to the impact of COVID but overall it is favorable.

For Florida Blue, all quality metrics are at or above the market for the month of July 2021. Mr. Malcolm noted that nephropathy screening has been replaced by colorectal cancer screening and the ACO is exceeding the market at this time in that metric. Generic Dispensing Rate remains at 83.1% but noted that there is a large HIV population so the options for generic medications is lower for this population. Florida Blue does not have the same generic efficiency rate calculation.

B. **Clinical Guidelines:** Mr. Malcolm noted that one guideline was approved at the last meeting, bringing the total to 31. Mr. Malcolm noted that there has been discussion around reviewing Use of Imaging for Low Back Pain guideline and that there is a consensus to keep the language regarding use of chiropractic medicine in the guideline. Mr. Malcolm deferred to Dr. Foster for comment and to request a vote on the metric.

Clinical Guideline for Board Approval

- 2022 Use of Imaging in Low Back Pain

Chair Foster stated that he understands the position of the Clinical Guidelines committee to retain the language around chiropractic medicine. He stated that he understands the rationale and while he does not agree personally, he will move to advance the guideline for approval.

**MOTION:** It was moved by Dr. Foster, seconded by Dr. Calvo to:

*Approve the 2022 Low Back Pain Imaging Guideline*

C. **Infrastructure and Data Analytics:** Mr. Malcolm noted that the Customer Relationship Management (CRM) software implementation started on February 7 and will continue for about six months. Mr. Malcom noted that this will assist with tracking patients when the...
present to the hospital for ER or inpatient care and assist with streamlining the process for closing care gaps.

Mr. Malcolm noted also that the Cerner Annual Health Check to review Population Health utilization of the software. Mr. Malcolm noted that the feedback from Cerner was positive and noted there are some optimizations that will be implemented in the coming weeks to further improve the software. Dr. Calvo and Mr. Malcolm will be meeting on February 14 to have the HEDIS metrics updated in Cerner to assist with meeting quality metrics across all payers.

D. **Patient Engagement:** Mr. Malcolm reviewed trend of annual visits since 2017. Mr. Malcolm noted that despite the data not being complete, the number of visits completed is higher than all previous years and continues an upward trend.

E. **Physician Engagement:** Mr. Malcolm noted that there has been no change in the number of executed contracts and number of physicians remains at 32. Mr. Malcolm noted that there is one pediatrician who has some final questions prior to signing the agreement. Mr. Malcolm will follow up with the physician and enlist assistance from Mr. Ortiz for any legal questions that arise.

Mr. Malcolm noted that he and Dr. Foster have been visiting community physicians to deliver distribution checks from the Florida Blue shared savings. Mr. Malcolm noted that the physician they visited earlier today is interested in joining the Medicare ACO, should that come to fruition.

Mr. Malcolm noted that he is working with Alex Fernandez and David Weisman to identify physicians for outreach using data from admissions for Florida Blue and Cigna and that, as noted previously, contact has been made with the physician relations staff at the different hospitals to assist with outreach. Dr. Foster noted that the reception from the community physicians has been very positive. Dr. Foster noted the ability to engage with the office staff around leveraging RN Connect and other resources to further assist them.

Mr. Albee inquired about board specific outreach program to the physicians. Mr. Malcolm noted that the work with Dr. Foster and Alex is to identify additional physicians, including utilization of Intellimed to identify physicians who admit Florida Blue and Cigna patients. Mr. Malcolm noted that Mr. Weisman in managed care has been out this week but Mr. Malcolm will continue to work to meet with him on the status of contracting other payers as well.

**VII. BROWARD HEALTH SYSTEM UPDATE:** Mr. Hetlage reported:
The Bond rating for the District has been a B+++ for some time now and there has been a lot of work to improve this rating over the last few years. Mr. Hetlage noted that last week the Bond rating has been upgraded to A-. He stated that Moody’s will be coming in to review in the next week or two.

Mr. Hetlage noted that COVID cases continue to decline but there remain staffing challenges that are seen throughout the country.

Dr. Calvo inquired about what is involved in the ratings. Mr. Hetlage noted that there are many things involved in the determination. Leadership stability is a significant component and Mr. Strum’s addition to the team has been positive. Financial performance, which has been steady, is one item. Business practices and balance sheet were other examples given. Mr. Hetlage noted that there are wide array of components in the complex evaluation.

VIII. BOARD MEMBER COMMENTS / OPEN FORUM

Mr. Albee requested an update on the Medicare ACO. Mr. Malcolm noted that the preliminary application is due in June and that Mr. Ortiz has been advised about physicians that are interested in joining the Medicare ACO in order to maximize the number of Medicare beneficiaries in the initial application. Mr. Malcolm noted that the initial application is an intent to apply with subsequent components to the application.

Mr. Albee inquired about the status of the budget. Mr. Ortiz and Mr. Malcolm noted that there have been no additional legal expenses so far since the application has not been submitted.

Mr. Albee also requested that the agenda and items provided earlier in the cycle prior to subsequent meetings. Dr. Foster supported this request.

Dr. Foster asked that updates on the Medicare ACO be a line item on future meetings. He noted that the physicians were excited to join.

Alex Fernandez talked about the efforts to grow the ACO. He noted that Mr. Malcolm presented at the strategic planning meeting and that Mr. Weisman and Mr. Malcolm met to review some options to expand the ACO. He stated that Mr. Malcolm will be presenting at the hospital MORs to present the ACO outcomes. Mr. Fernandez noted identification of providers in the area with Blue Cross lives and how the business development. Mr. Fernandez noted the possibility of a dedicated business development person to follow the patients more closely.

Dr. Khan noted that he has had issues accessing the Electronic Health Record from his office. Mr. Hetlage provided information about the new minimum requirements as a result of a security patch. Mr. Hetlage will have someone in IT follow up with Dr. Khan.

I. ADJOURNMENT: 6:02 PM
Chair Foster entertained a motion to adjourn.

**MOTION** It was *moved*, by Mr. Albee *seconded* by Dr. Calvo to:

**Adjourn the February 2022 ACO Board of Directors meeting.**

Motion *carried* unanimously.

The next ACO Board of Director’s meeting will be held on March 9, 2022 at 5:30 PM via Microsoft Teams.